Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BMEA Biomea Fusion, Inc.

Not Yet Opened 07-02 16:00:00 EDT

4.43

+0.01

+0.23%

盘后4.48

+0.05+1.13%

19:38 EDT

High4.68	Low4.35	Vol703.02K
Open4.41	D1 Closing4.42	Amplitude7.50%
Mkt Cap159.23M	Tradable Cap86.16M	Total Shares35.94M
T/O3.16M	T/O Rate3.61%	Tradable Shares19.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":4.43,"timestamp":1719950400000,"preClose":4.42,"halted":0,"volume":703020,"hourTrading":{"tag":"盘后","latestPrice":4.48,"preClose":4.43,"latestTime":"19:38 EDT","volume":4082,"amount":18089.5,"timestamp":1719963490327},"delay":0,"floatShares":19450049,"shares":35944584,"eps":-3.566554,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"07-02 16:00:00 EDT","open":4.41,"high":4.6813,"low":4.35,"amount":3163336.9128,"amplitude":0.074955,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.566554,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1719993600000},"marketStatusCode":0,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":4.42,"preHourTrading":{"tag":"盘前","latestPrice":4.4324,"preClose":4.42,"latestTime":"09:27 EDT","volume":494,"amount":2189.0269284,"timestamp":1719926835805},"postHourTrading":{"tag":"盘后","latestPrice":4.48,"preClose":4.43,"latestTime":"19:38 EDT","volume":4082,"amount":18089.5,"timestamp":1719963490327},"volumeRatio":0.585063,"impliedVol":1.2865,"impliedVolPercentile":0.7143},"requestUrl":"/m/hq/s/BMEA","defaultTab":"news","newsList":[{"id":"2447628250","title":"Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?","url":"https://stock-news.laohu8.com/highlight/detail?id=2447628250","media":"Insider Monkey","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2447628250?lang=en_us&edition=fundamental","pubTime":"2024-06-30 08:32","pubTimestamp":1719707541,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Biomea Fusion, Inc.  stands against the other biotech penny stocks.Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities. In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities. Particularly biotech is anticipated to profit, despite the dangers of continuous mergers and acquisitions. Traders ought to exercise caution. With an 11.8% CAGR, the worldwide biotechnology market is expected to reach USD 4.25 trillion by 2033. It is expanding quickly. The U.S. market is projected to increase at an 11.90% CAGR to reach USD 763.82 billion by 2033 from its 2023 valuation of USD 246.18 billion. In 2023, the U.S. led North America in terms of revenue share.\"[Biotech] has been one of the worst spaces in all of the equity market since mid-2021. We've barely seen any positive acti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rc33b3QWKFbOJEjYacTUCw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a3eb6b253987ff6de821a395fc8b397a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rc33b3QWKFbOJEjYacTUCw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a3eb6b253987ff6de821a395fc8b397a"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomea-fusion-inc-bmea-why-003221548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMEA"],"gpt_icon":0},{"id":"2446819413","title":"Biomea Fusion Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446819413","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446819413?lang=en_us&edition=fundamental","pubTime":"2024-06-25 19:08","pubTimestamp":1719313680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 25, 2024 07:08 ET (11:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2446815112","title":"Buy Rating Affirmed for Biomea Fusion Amid Temporary Clinical Hold and Positive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2446815112","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446815112?lang=en_us&edition=fundamental","pubTime":"2024-06-25 18:35","pubTimestamp":1719311751,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), reducing the price target to $15.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-biomea-fusion-amid-temporary-clinical-hold-and-positive-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-biomea-fusion-amid-temporary-clinical-hold-and-positive-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0},{"id":"2443270476","title":"Franco Valle Bought 42% More Shares In Biomea Fusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2443270476","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443270476?lang=en_us&edition=fundamental","pubTime":"2024-06-14 20:18","pubTimestamp":1718367535,"startTime":"0","endTime":"0","summary":"Even if it's not a huge purchase, we think it was good to see that Franco Valle, the CFO & Principal Accounting Officer of Biomea Fusion, Inc.  recently shelled out US$55k to buy stock, at US$4.43 per share. That purchase might not be huge but it did increase their holding by 42%.Biomea Fusion Insider Transactions Over The Last Year. Notably, that recent purchase by Franco Valle is the biggest insider purchase of Biomea Fusion shares that we've seen in the last year. We do like to see buying, but this purchase was made at well below the current price of US$5.81. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.You can see a visual depiction of insider transactions  over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!For the purposes of this article, insiders are those individuals who report their transactions to the ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/franco-valle-bought-42-more-121855113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMEA","BK4539","BK4139","BK4585"],"gpt_icon":0},{"id":"2442031363","title":"Truist cuts Biomea Fusion to hold, cites clinical hold uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2442031363","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442031363?lang=en_us&edition=fundamental","pubTime":"2024-06-11 22:52","pubTimestamp":1718117574,"startTime":"0","endTime":"0","summary":"Truist Securities has lowered its rating on Biomea Fusion  to hold, citing uncertainty about the timeline for resolving an FDA clinical hold on the company’s lead asset BMF-219. “We expect the stock to trade in a band, following the pullback, until the hold is lifted and there is clarity on a path forward for the drug,” Truist said in its note. Truist also withdrew its price target on the stock, citing recent volatility in the shares and low share price.  “If the data in Q4 are positive and if the clinical hold is lifted, we see potential for the stock to appreciate,” it added.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1384646810/image_1384646810.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1384646810/image_1384646810.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4114881-truist-cuts-biomea-fusion-to-hold-cites-clinical-hold-uncertainty","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4539","BMEA","BK4139","BK4585"],"gpt_icon":0},{"id":"2442398979","title":"Biomea Fusion Cut to Hold From Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2442398979","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442398979?lang=en_us&edition=fundamental","pubTime":"2024-06-11 20:17","pubTimestamp":1718108220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2024 08:17 ET (12:17 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4539","BK4139","BK4585"],"gpt_icon":0},{"id":"2442364975","title":"BUZZ-Biomea Fusion falls as Truist cuts to \"hold\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2442364975","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442364975?lang=en_us&edition=fundamental","pubTime":"2024-06-11 19:25","pubTimestamp":1718105101,"startTime":"0","endTime":"0","summary":"** Biomea Fusion's shares    fall ~5% to $4.10 premarket as Truist Securities cuts to \"hold\" from \"buy\"   ** US FDA placed clinical hold on studies of Biomea's diabetes drug on June 6 due to liver toxicity concerns   ** Truist says lack of details on those concerns makes its tough to estimate a resolution timeline and adds that cash runway concerns are keeping investors on the sidelines    ** Expects stock to trade in a band until FDA hold is lifted   ** Stock has sunk 62% in 2 sessions since the ruling   ** Truist does not assign a PT due to recent volatility   ** Now 3 brokers, incl Truist, rate BMEA 'hold' and 5 'buy'/'strong buy' - LSEG data   ** 4 brokers have changed their PTs since the FDA; their PTs are $5, $10, $21 and $45 -LSEG data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BMEA"],"gpt_icon":0},{"id":"2442352681","title":"Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2442352681","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442352681?lang=en_us&edition=fundamental","pubTime":"2024-06-11 17:08","pubTimestamp":1718096901,"startTime":"0","endTime":"0","summary":"Price: 4.2800, Change: -0.03, Percent Change: -0.70","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMEA"],"gpt_icon":0},{"id":"2442433777","title":"U.S. RESEARCH ROUNDUP-Biomea Fusion, Enphase Energy, Perion Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2442433777","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442433777?lang=en_us&edition=fundamental","pubTime":"2024-06-11 15:20","pubTimestamp":1718090417,"startTime":"0","endTime":"0","summary":"June 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Biomea Fusion, Enphase Energy and Perion Network, on Tuesday.    H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GM","LU0289960550.SGD","LU1814569148.SGD","BK4218","HSBC","FCEL","SNX","BK4139","BK4588","CFLT","NUE","RLJ","LU2430703095.HKD","BK4581","BK4075","BK4181","LU2430703251.USD","CRK","LU1023059063.AUD","GOOGL","WMT","ENPH","LU0130102774.USD","LLY","BMEA","F","LBPH","LU0689472784.USD","ELVN","LU0198837287.USD","LU1548497426.USD","PROK","NVDA","LU0708995401.HKD","BK4170","LU2430703178.SGD","MU","BK4585","BK4574","LU1280957306.USD","LU2265009873.SGD","PERI","LU0820561909.HKD","CLF","BTI","BK4504","LU0109391861.USD","WDC","SKYE","LU0061475181.USD"],"gpt_icon":1},{"id":"2442338343","title":"Tracking Baker Brothers Portfolio - Q1 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2442338343","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2442338343?lang=en_us&edition=fundamental","pubTime":"2024-06-11 12:24","pubTimestamp":1718079843,"startTime":"0","endTime":"0","summary":"Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B.The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma.Baker Brothers has h","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4698516-tracking-baker-brothers-portfolio-q1-2024-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IGMS","DNLI","TSVT","ACHL","MDGL","ACAD","RYTM","LU0820561818.USD","RVMD","INCY","BGNE","CABA","TRDA","SGMT","VTVT","EWTX","LU1066053197.SGD","OPT","AVTE","BCYC","RARE","BMEA","BMY","NRIX","LU0109394709.USD","HOOK","ROIV","ABBV","IMTX","AKRO","CERS","KYMR","LU0820561909.HKD","LU1496350171.SGD","TCRX","BCRX","ADAP","ALGS","REPL","ABCL","GLUE","ATHA","ARGX","MRTX","LU0689472784.USD","IMCR","PFE","KOD","CERE","KALA"],"gpt_icon":0},{"id":"2441013888","title":"Sector Update: Health Care Stocks Higher Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2441013888","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441013888?lang=en_us&edition=fundamental","pubTime":"2024-06-08 04:01","pubTimestamp":1717790514,"startTime":"0","endTime":"0","summary":"Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding about 0.2%.The iShares Biotechnology ETF (IBB) fell 0.5%.In","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","XLV","IBB","BK4128","BK4588","BK4082","BMEA","BK4121","BK4139","BK4581","ASXC","CDXC","LU0321505439.SGD","LU0321505868.SGD","WBA","BK4585","WBA.AU"],"gpt_icon":0},{"id":"2441099836","title":"Biomea Fusion Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441099836","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441099836?lang=en_us&edition=fundamental","pubTime":"2024-06-08 01:07","pubTimestamp":1717780020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 07, 2024 13:07 ET (17:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2441706916","title":"US Stocks Lower; Nonfarm Payrolls Increase More Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2441706916","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441706916?lang=en_us&edition=fundamental","pubTime":"2024-06-07 21:50","pubTimestamp":1717768225,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/06/39227786/us-stocks-lower-nonfarm-payrolls-increase-more-than-expected","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","QID","NQmain","BK4139",".IXIC","QLD","BK4205","BK4233","BK4077","SQQQ","VERO","BK4082","QQQ","BK4007","BNED","SCNI","BMEA","PSQ","BK4585","MNQmain","TQQQ","LFLY","TPHS","BK4200"],"gpt_icon":0},{"id":"2441806656","title":"Scotiabank Cuts Price Target on Biomea Fusion to $21 From $41, Maintains Sector Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2441806656","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441806656?lang=en_us&edition=fundamental","pubTime":"2024-06-07 21:26","pubTimestamp":1717766778,"startTime":"0","endTime":"0","summary":"Biomea Fusion (BMEA) has an average outperform rating and price target range of $15 to $60, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMEA"],"gpt_icon":0},{"id":"2441651200","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2441651200","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441651200?lang=en_us&edition=fundamental","pubTime":"2024-06-07 21:13","pubTimestamp":1717766006,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed pre-bell Friday, with the Health Care Select Sector SPDR Fund  slightly higher and the iShares Biotechnology ETF  declining by 1.5%.Geron  shares were up past 19% after the company said it received approval from the US Food and Drug Administration for its drug Rytelo to treat adult patients with lower-risk myelodysplastic syndrome, a type of leukemia.Biomea Fusion  stock was down more than 65% after the company said it was notified that the US Food and Drug Administration placed a full clinical hold on the phase I/II trials of its investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes.Semler Scientific  shares were down more than 2% after the company said it filed a registration statement for the offering of up to $150 million worth of various securities, including common shares, debt securities, units, and warrants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SMLR","BK4585","BK4082","BK4581","BK4588","XLV","BMEA","BK4139","IBB","GERN","BK4539"],"gpt_icon":0},{"id":"2441061778","title":"Biomea Fusion cut at Barclays following clinical hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2441061778","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441061778?lang=en_us&edition=fundamental","pubTime":"2024-06-07 20:59","pubTimestamp":1717765140,"startTime":"0","endTime":"0","summary":"Barclays has downgraded Biomea Fusion  to equal weight from overweight citing the June 6 announcement that the U.S. FDA placed a full clinical hold on phase 1/2 trials for BMF-219 for type 1 and type 2 diabetes. The firm also lowered its price target to $5 from $30 .  Analyst Peter Lawson said the downgrade is being done until there is resolution on the hold, which was caused by potential drug-induced liver toxicity. Despite the setback, he expects initial expansion data from the type 3 trial, COVALENT-111, in the second half of the year as well as phase 2 data in from the open-label portion of the type 1 COVALENT-112 trial by the end of the year as well.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173024040/image_173024040.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173024040/image_173024040.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4114067-biomea-fusion-cut-barclays-following-clinical-hold","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","BMEA","BK4139","BK4539"],"gpt_icon":0},{"id":"2441206348","title":"Jobs Growth Tops Forecasts as US Equity Futures Post Narrow Losses Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2441206348","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441206348?lang=en_us&edition=fundamental","pubTime":"2024-06-07 20:57","pubTimestamp":1717765025,"startTime":"0","endTime":"0","summary":"US equity futures were cautiously lower ahead of Friday's opening bell as traders digested the pivotal monthly jobs report.Dow Jones Industrial Average futures fell 0.3%, S&P 500 futures declined 0.3%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4212","POST","DOG","DDM","BK4539","QLD","BK4588","EQR","PSQ","QQQ","DXD","UDOW","BRZE","MNQmain","BK4585",".IXIC","BK4139","SDOW",".DJI","SQQQ","BMEA","GERN",".SPX","DJX","QID","NQmain","TQQQ","BK4023","BK4215"],"gpt_icon":0},{"id":"2441706350","title":"Optimism for Biomea Fusion’s BMF-219 Continues Despite Clinical Hold: A Buy Rating Justified","url":"https://stock-news.laohu8.com/highlight/detail?id=2441706350","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441706350?lang=en_us&edition=fundamental","pubTime":"2024-06-07 20:45","pubTimestamp":1717764322,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimism-for-biomea-fusions-bmf-219-continues-despite-clinical-hold-a-buy-rating-justified?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimism-for-biomea-fusions-bmf-219-continues-despite-clinical-hold-a-buy-rating-justified?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":-0.1497},{"period":"1month","weight":-0.5789},{"period":"3month","weight":-0.6826},{"period":"6month","weight":-0.7105},{"period":"1year","weight":-0.7934},{"period":"ytd","weight":-0.6949}],"compareEarnings":[{"period":"1week","weight":0.0077},{"period":"1month","weight":0.041},{"period":"3month","weight":0.057},{"period":"6month","weight":0.1749},{"period":"1year","weight":0.2371},{"period":"ytd","weight":0.1551}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.111851},{"month":2,"riseRate":0.333333,"avgChangeRate":0.070637},{"month":3,"riseRate":0.333333,"avgChangeRate":0.321728},{"month":4,"riseRate":0,"avgChangeRate":-0.21954},{"month":5,"riseRate":0.75,"avgChangeRate":0.245778},{"month":6,"riseRate":0.25,"avgChangeRate":0.039512},{"month":7,"riseRate":0.25,"avgChangeRate":-0.068028},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.033091},{"month":9,"riseRate":0,"avgChangeRate":-0.158617},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.078427},{"month":11,"riseRate":0.666667,"avgChangeRate":0.084011},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.082267}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction